Market Research Logo

Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)

Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)

Scope of the Report

The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.

Country Coverage

United states
United Kingdom
India
China
Japan

Company Coverage

Agile Therapeutics Inc.
Actavis Plc.
Bayer Healthcare
Teva Pharmaceuticals

Executive Summary

Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.

Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.


1. Executive Summary
2. Combined Hormonal Contraceptives Market: An Overview
2.1 Definition
2.2 History
2.3 Classification
>Table 1: Types of Combined Hormonal Contraceptives
2.3.1 Combined Oral Contraceptive Pills
Table 2: Fixed Dose Microgynon® 30 ED
2.3.2 Combined Vaginal Rings
Table 3: Combined Vaginal Rings
2.3.3 Combined Transdermal Patches
Table 4: Twirla Patch Components
2.3.4 Combined Injectable Birth Control
2.3.5 Combined Emergency Contraceptive Pills
2.4 Mechanism of Action
Table 5: Mechanism of Action
2.5 Components of CHCs
2.6 Advantages of Combined Hormonal Contraceptives
2.7 Disadvantages of Combined Hormonal Contraceptives
2.8 Contraindications
2.9 Serious Risks
3. Combined Hormonal Contraceptives(CHC) Market Analysis
3.1 Global CHC Market Sizing and Growth
Table 6: Annual Sales of Global CHC Market; 2008-2013 (US$ Million)
Table 7: Global CHC Market Size by Annual Sales Forecasted; 2014-2019E (US$ Million)
3.2 Global CHC Market Breakup: Branded vs. Generic
Table 8: Global CHC Market Breakup: Branded vs. Generic
3.3 CHC Generic Market
Table 9: Annual Sales of Global Generic CHC Market; 2008-2013 (US$ Million)
3.4 Global CHC Branded Market
Table 10: Annual Sales of Global Branded CHC Market; 2008-2013 (US$ Million)
4. Combined Hormonal Contraceptives(CHC): Market Share Analysis
4.2.1 Global CHC Market Share by Class
Table 11: Global CHC Market Share by Class; 2013
4.2.2 Global CHC Market Share by Key Players
Table 12: Global CHC Market Share by Key Players; 2013
4.2.3 Global CHC Market Share by Key Products
Table 13: Global CHC Market Share by Key Products; 2013
5. Combined Hormonal Contraceptives(CHC): Country Analysis
Table 14: Women Population Aged 15-49 years in Seven Major Markets; 2013 (Thousands)
Table 15: Women Population Aged 15-49 years in Seven Major Market taking Hormonal contraception by class; 2010-2013 (Thousands)
Table 16: Women Population Aged 15-49 years in Seven Major Market taking Hormonal Contraception Forecasted; 2014-2019 (Thousands)
5.1 The U.S. Combined Hormonal Contraceptives Market
Table A: Key Oral Contraceptives (OC) TRx (million)
Table 17: U.S. Oral Contraceptive TRx Breakdown; 2013 (US$ 4 billion)
Table 18: U.S. Oral Contraceptive Sales Breakdown; 2013 (US$ 4 billion)
Table 19: Indian versus MNC generic’s TRx share; 2013
5.2 The UK Combined Hormonal Contraceptives Market
5.3 Japan Combined Hormonal Contraceptives Market
5.4 India Combined Hormonal Contraceptives Market
5.5 China Combined Hormonal Contraceptives Market
6. Market Dynamics: Combined Hormonal Contraceptives(CHC) Market
6.1 Growth Drivers
6.1.1 Rise in Healthcare Expenditure
Table 20: Healthcare Expenditure Worldwide; 2007-2013 (US$ Million)
6.1.2 Growth in the U.S. Contraceptive Market
Table 21: Population - Women aged 15-44 years in the US: 2008-2020 (Thousands)
Table 22: US CHC Market -Quarterly Prescription Growth (%)
6.1.3 Government Initiatives
6.1.4 The Prescriber Base is Easily Targeted
6.2 Challenges
6.2.1 Strict Regulatory Compliance
6.2.2 Serious Adverse Events
6.3 Market Trends
6.3.1 Significant M&A activity in Women’s Health Market
6.3.2 Use of Newer Progestins
7. Competitive Landscape
Table B: Leading Players of Hormonal Contraceptives Market
Table C: Hormonal Contraception Market: Key Players and their Marketed Products and Pipeline Products
Table 23: Global Sales of Key Products: FY 2013 (US$ Million)
8. Company Profiles: Combined Hormonal Contraceptives(CHC) Market
8.1 Agile therapeutics, Inc.
8.1.1 Business OTableverview
Table 24: Twirla Patch Components
Table 25: Skinfusion Technology
Table D: Agile Therapeutics Product Pipeline
8.1.2 Financial Overview
Table 26: Agile Net Revenue Forecasted: 2016-2021 (US$ Million)
8.1.3 Business Strategy
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Financial Overview
Table 27: Actavis Plc. Net Revenue (consolidated): 2009-12 (US$ Million)
Table 28: Actavis specialty brand; Net Revenue and Product Sales (consolidated): 2012-13 (US$ Million)
8.2.3 Business Strategy
8.3 Bayer Healthcare
8.3.1 Business Overview
8.3.2 Financial Overview
Table 29: Bayer Pharmaceuticals, Net Sales: 2010-13 (US$ Billion)
Table 30: YAZ/Yashmin/Yasminelle, Net sales: 2010-13 (US$ Million)
8.3.3 Business Strategy
8.4 Teva Pharmaceutical Industries Limited
8.4.1 Business Overview
8.4.2 Financial Overview
Table 31: Teva Specialty Medicines Net Revenue by Region: 2013 (US$ Billion)
Table 32: Teva Women Health Products Net Revenue: FY 2011-13 (US$ Million)
8.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report